CN113038930A - 冻干形式的药物组合物 - Google Patents

冻干形式的药物组合物 Download PDF

Info

Publication number
CN113038930A
CN113038930A CN201980043201.0A CN201980043201A CN113038930A CN 113038930 A CN113038930 A CN 113038930A CN 201980043201 A CN201980043201 A CN 201980043201A CN 113038930 A CN113038930 A CN 113038930A
Authority
CN
China
Prior art keywords
pharmaceutical composition
composition
lyophilized
liposome
dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980043201.0A
Other languages
English (en)
Chinese (zh)
Inventor
奥利弗·登克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respiratory Therapy Co
Original Assignee
Respiratory Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respiratory Therapy Co filed Critical Respiratory Therapy Co
Publication of CN113038930A publication Critical patent/CN113038930A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980043201.0A 2018-06-27 2019-06-25 冻干形式的药物组合物 Pending CN113038930A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18180177 2018-06-27
EP18180177.0 2018-06-27
PCT/EP2019/066875 WO2020002353A1 (en) 2018-06-27 2019-06-25 Pharmaceutical compositions in lyophilized form

Publications (1)

Publication Number Publication Date
CN113038930A true CN113038930A (zh) 2021-06-25

Family

ID=62814888

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980043201.0A Pending CN113038930A (zh) 2018-06-27 2019-06-25 冻干形式的药物组合物

Country Status (11)

Country Link
US (2) US20210244664A1 (https=)
EP (1) EP3813788A1 (https=)
JP (1) JP7401471B2 (https=)
CN (1) CN113038930A (https=)
AU (1) AU2019295027B2 (https=)
BR (1) BR112020026629A2 (https=)
CO (1) CO2021000223A2 (https=)
EA (1) EA202092893A1 (https=)
IL (1) IL279760B2 (https=)
MX (1) MX2020013831A (https=)
WO (1) WO2020002353A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025204688A1 (ja) * 2024-03-26 2025-10-02 株式会社ダイセル リン脂質膜保護用液体組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
EP0208764A4 (en) 1985-01-11 1987-10-08 Univ California METHOD FOR PRESERVING LIPOSOMES.
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
DE69211691T2 (de) 1991-04-19 1997-01-16 Nexstar Pharmaceuticals Inc., Boulder, Col. Pharmazeutische formulierung und pharmazeutisches verfahren
WO1996040064A1 (en) 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US5958378A (en) * 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
IT1289938B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
AU2003237863A1 (en) 2002-05-20 2003-12-12 Research Development Foundation Aerosol drug inhibition of lung metastases
EP1687635A2 (en) * 2003-11-26 2006-08-09 Applera Corporation Ligand-containing micelles and uses thereof
EP1750671B1 (en) * 2004-06-03 2008-10-15 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
DE102006051512A1 (de) * 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
CA2631243A1 (en) * 2005-12-08 2007-06-14 Wyeth Liposomal compositions
EP1797895A1 (en) * 2005-12-16 2007-06-20 Pevion Biotech Ltd. An adjuvant system comprising virosomes and liposomes
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
US20140127288A1 (en) * 2011-05-17 2014-05-08 Mitsubishi Gas Chemical Company, Inc. Liposome containing pyrroloquinoline quinone and sugar
EP3069711A1 (en) * 2015-03-16 2016-09-21 PARI Pharma GmbH Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection

Also Published As

Publication number Publication date
JP2021528450A (ja) 2021-10-21
US20230301914A1 (en) 2023-09-28
AU2019295027B2 (en) 2024-09-19
CO2021000223A2 (es) 2021-01-18
IL279760B2 (en) 2025-10-01
WO2020002353A1 (en) 2020-01-02
CA3104445A1 (en) 2020-01-02
IL279760A (en) 2021-03-01
AU2019295027A1 (en) 2020-12-24
US20210244664A1 (en) 2021-08-12
IL279760B1 (en) 2025-06-01
MX2020013831A (es) 2021-03-25
BR112020026629A2 (pt) 2021-03-23
JP7401471B2 (ja) 2023-12-19
EP3813788A1 (en) 2021-05-05
EA202092893A1 (ru) 2021-04-19

Similar Documents

Publication Publication Date Title
Courrier et al. Pulmonary drug delivery systems: recent developments and prospects
CN101474155B (zh) 注射用肺靶向载药前体脂质体及其使用方法
RU2421209C2 (ru) Фармацевтические композиции, содержащие циклоспорин
US8586527B2 (en) Cerivastatin to treat pulmonary disorders
TW202011941A (zh) 用於治療肺部疾病的可吸入的緩釋組成物
JP2008503586A (ja) アンフォテリシンｂを含む組成物、方法、およびシステム
CN107427482A (zh) 凝血酸的多囊脂质体制剂
CN101653414A (zh) 多西他赛长循环固体脂质纳米粒及其制备方法
JP3245955B2 (ja) リポソーム
US20230301914A1 (en) Pharmaceutical compositions in lyophilized form
Chordiya et al. Proliposomes: a potential colloidal carrier for drug delivery applications
CA3104445C (en) Pharmaceutical compositions in lyophilized form
JP7726884B2 (ja) 吸入可能な免疫抑制活性成分を含む分散液の調製のためのプロセス
CA3161686C (en) Process for the preparation of dispersions comprising inhalable immunosuppressive active ingredients
EA048772B1 (ru) Фармацевтические композиции в лиофилизированной форме
Parmar et al. Proliposome: Novel drug delivery system
CN101278913B (zh) 一种peg衍生化磷脂包载前列腺素e1的胶束制剂
CN106580928A (zh) 穿心莲内酯纳米吸入剂及其在治疗细菌性肺炎中的应用
EA046086B1 (ru) Способ получения дисперсий, содержащих ингаляционные иммуносупрессивные активные ингредиенты
TWI630000B (zh) 安定性高藥物劑載之奈米載劑，其製備方法及其用途
KR20240096358A (ko) 나노 입자를 포함하는 흡입 제형 및 이의 제조 방법
EA044593B1 (ru) Ингаляционные композиции, содержащие макроциклические иммуносупрессанты

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination